CURRICULUM VITAE

Neil Turk Feldman, M.D.
2525 Pasadena Avenue South, Suite S
St. Petersburg, FL 33707
Phone 727.360.0853
Fax 727.367.3735

EDUCATION

1964	BS, University of Maryland, College Park, Maryland
1968	M.D., Washington University School of Medicine, St. Louis Missouri
1969	Intern, Ward Medical Service, Barnes Hospital, St. Louis, Missouri
1969-1970	Assistant Resident, Ward Medical Service, Barnes Hospital, St. Louis, Missouri
1972-1973	Senior Resident, Harvard Medical Unit, Boston City Hospital, Boston Massachusetts
1973	Clinical and Research Fellow, Division of Respiratory Diseases, Harvard Medical Unit, Thorndike and Channing Laboratories, Boston City Hospital, Boston, Massachusetts
1976	Clinical and Research Fellow, Pulmonary Division, Brigham and Women's Hospital, Boston, Massachusetts.

MILITARY

1970-1972	Major, U.S. Air Force, Otis AFB, Massachusetts

EXPERIENCE

1974	Assistant Physician, Beth Israel Hospital, Harvard University, Boston, Massachusetts
1974	Instructor in Medicine, Harvard Medical School, Boston Massachusetts
1974	Junior Associate in Medicine (Respiratory Division), Peter Bent Brigham

	Hospital Harvard University, Boston, Massachusetts
1974	Pulmonary Consultant, Robert Breck Brigham Hospital, Harvard University, Boston, Massachusetts
1975	Assistant Director of Respiratory Care, Department of Anesthesiology, Peter Bent Brigham Hospital, Harvard University, Boston, Massachusetts
1976	Medical Director, Respiratory Therapy, Sidney Farber Cancer Center, Harvard University, Boston, Massachusetts
1977	Assistant Professor of Medicine, Harvard Medical School, Boston, Massachusetts
1977	Pulmonary Consultant, Department of Public Welfare, Commonwealth of Massachusetts, Boston, Massachusetts
1978	Private Practice of Pulmonary Medicine, 2525 Pasadena Avenue South St. Petersburg, Florida
1978	Medical Director, Respiratory Therapy, Palms of Pasadena Hospital, St. Petersburg, Florida
1978	Director, Pulmonary Physiology Laboratory, Palms of Pasadena Hospital, St. Petersburg, Florida
1979	Director, Respiratory Intensive Care Unit, Palms of Pasadena Hospital, St. Petersburg, Florida
1985	Founded St. Petersburg Sleep Disorder Center at Palms of Pasadena Hospital St. Petersburg, Florida. Fully Accredited by the ASDA in 1992 and serves as Medical Director
2002	Founded Clinical Research Group of St. Petersburg, Inc.

MEMBERSHIPS

1968	Alpha Omega Alpha, Honor Medical Society
1972	American Thoracic Society American Federation for Clinical Research American College of Chest Physicians

1978	Pinellas County Medical Society American Medical Association Florida Medical Association
1981	American Sleep Disorder Association
1981	American Academy of Sleep Medicine
1985	Southern Sleep Society
1987	Founded Florida Narcolepsy Association
1991	National Sleep Foundation

CERTIFICATIONS

1973	American Board of Internal Medicine
1976	American Board of Internal Medicine, Subspecialty, Pulmonary Diseases
1990	American Board of Sleep Medicine

CLINICAL RESEARCH EXPERIENCE

1995	Principal Investigator: Phase III, randomized, double-blind, placebo-controlled trial of *Modafinil* in the treatment of narcolepsy for Cephalon, Inc.
1996	Principal Investigator: Phase III, open label trial of *Modafinil* in the treatment of narcolepsy for Cephalon, Inc.
1996	Principal Investigator: A survey of narcolepsy patients on *methlphenidate* treatment for Cephalon, Inc.
1997	Principal Investigator: Phase III, randomized, double-blind, placebo-controlled, parallel group, multi-center trail comparing the effects of three doses of orally administered *Xyrem* (gamma-hydroxybutyrate) with placebo for the treatment of narcolepsy for Orphan Medical, Inc.
1998	Principal Investigator: Phase III, randomized, double -blind, placebo-controlled trial of a melatonin agonist in the treatment of insomnia in the

elderly for Bristol-Myers Squibb, Inc.

1998 Principal Investigator: Phase IIIb, A six week open-label study of the safety and efficacy of *Provigil* (Modafinil) in patients switching from stimulant therapy for narcolepsy and associated excessive daytime sleepiness for Cephalon, Inc.

1999 Principal Investigator: Phase III, Long term, open label, multi-center extension trial of *Xyrem* oral solution for the treatment of narcolepsy for Orphan Medical, Inc.

1999 Principal Investigator: Phase III, Open-label, multi-center, six month trial of *Xyrem* oral solution for the treatment of narcolepsy in study drug naive patients for Orphan Medical, Inc.

1999 Principal Investigator: Phase IIIb, A four-week double blind, placebo controlled, multi-center, randomized, parallel group study of the effect of *Provigil* in excessive daytime sleepiness and vigilance in obstructive sleep apnea in patients treated with nasal CPAP for Cephalon, Inc.

1999 Principal Investigator: Phase II, double-blind, parallel, placebo-controlled, multi-center, polysomographic study of the effects of L-759,274 and *Zolpidem* in patients with chronic insomnia for Merck and Company, Inc.

1999 Principal Investigator: A double-blind, parallel, placebo-controlled, multicenter, polysomnographic study of the effects of L-762274 and *Zolpidem* in patients with chronic insomnia for Merck and Company, Inc.

2000 Principal Investigator: An open-label, multicenter, six-month trial of *Xyrem* (sodium oxybate oral solution) for the treatment of narcolepsy for Orhpan, Inc.

2001 Principal Investigator: A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of 12 weeks of *Provigil* (Modafinil) therapy at a dosage of 200 mg once daily as treatment for adults with excessive daytime sleepiness associated with chronic shift work sleep disorder, followed by a 12-month open label extension period for Cephalon, Inc.

2001 Principal Investigator: A randomized, double-blind, active-and-placebo' controlled 4-way crossover study of the safety and efficacy of PD 0200390, *Zolpidem* and placebo in ordinary insomnia for Pfizer.

2001 Principal Investigator: A randomized, double-blind, placebo-controlled, Parallel, 2-week, objective efficacy and safety study of *Eszopiclone* in Elderly subjects with primary insomnia for Sepracor, Inc.

2002 Principal Investigator: A randomized, double-blind, placebo-controlled, dose response study to assess the efficacy and safety of a modified release formulation of NBI-34060 in elderly patients with chronic sleep maintenance insomnia for Neurocrine.

2002 Principal Investigator: A 12-week, double-blind, placebo-controlled, parallel study to assess the efficacy, safety, and tolerability of *Ropinirole* in subjects with restless leg syndrome (RLS) suffering from periodic leg movements of sleep (PLMS) for GlakoSmithKline, Inc.

2002 Principal Investigator: A 30-day multicenter, double-blind, randomized, Parallel, placebo-controlled study to evaluate the safety and efficacy of ANPH 101 sleep maintenance in adult patients with chronic primary insomnia for Ancile.

2002 Principle Investigator: Comparison of the efficacy and safety of *Zolpidem-MR 12.5 mg* and placebo in patients with primary insomnia for Sanofi.

2002 Principal Investigator: A phase III, randomized, double-blind, placebo-Controlled, outpatient study to assess the long term safety and efficacy of two dose levels of a modified release formulation of *NBI-34060* in adult patients with primary insomnia for Neurocrine, Inc.

2002 Principal Investigator: A phase II randomized, double-blind, 5-way-cross over study to evaluate the efficacy of *Gaboxadol (5, 10, and 15 mg)* and *Zolpidem (10 mg)* versus placebo in a model of transient insomnia for Lundbeck.

2002 Principal Investigator: A Randomized, latin-square, double-blind, placebo-controlled study of the safety and efficacy of *Gabitril* in patients with primary insomnia for Cephalon, Inc.

2003 Principal Investigator: A phase III, randomized, double-blind, placebo controlled, outpatient study to assess the long-term safety and efficacy of two dose levels of a modified release formulation of *NBI-34060* in adult patients with primary insomnia for Neurocrine, Inc.

2003 Principal Investigator: A six-month, chronic efficacy and safety study of *Eszopiclone* in adult subjects with primary insomnia for Sepracor, Inc.

2003 Principal Investigator: A phase III, randomized, double-blind, placebo-controlled, safety and efficacy study of *TAK-375* in elderly subjects with chronic insomnia for Takeda.

2003 Principal Investigator: A phase III, randomized, double-blind, placebo-controlled, outpatient safety and efficacy study of TAK-375 in adults with chronic insomnia for Takeda.

2003 Principal Investigator: A randomized, placebo-controlled clinical trial of the effects of orally administered *Xyrem* (*sodium oxybate*) and *Zolpidem* on sleep disordered breathing in obstructive sleep apnea patients for Orphan.

2003 Principal Investigator: A randomized, double-blind, double-dummy, placebo controlled, parallel-group, multicenter, trial comparing the effects of orally administered *Xyrem (sodium oxybate)* and *Modafinil* with placebo in the treatment of daytime sleepiness in narcolepsy for Orphan.

2003 Principal Investigator: A randomized, placebo-controlled, clinical trial of the effects of orally administered *Xyrem (sodium oxybate)* and *Zolpidem* on sleep disordered breathing in obstructive sleep apnea patients for Orphan.

2004 Principal Investigator: A 12-month, open-label, flexible dosage (100-250 mg/day) of the safety and efficacy of CEP-10953 in the treatment of patients with excessive daytime sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome or chronic shift work for Cephalon, Inc.

2004 Principal Investigator: A phase II, randomized, double-blind, placebo-controlled, dose response study to assess the efficacy and safety of *Doxepin* in patients with primary sleep maintenance insomnia for Somaxon, Inc.

2004 Principal Investigator: A 12-week, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of *CEP-100956 (150 and 250 mg/day)* as treatment for adults with residual sleepiness associated with obstructive sleep apnea for Cephalon, Inc.

2004 Principal Investigator: A 12-month, open-label, flexible dosage (100-250 mg/day) study of the safety and efficacy of *CEP-10953* in the treatment of patients with excessive daytime sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome or chronic work shift sleep disorder for Cephalon, Inc.

2004 Principal Investigator: Evaluation of the long term efficacy and safety of *Zolpidem-MR 12.5 mg* compared to placebo when both are administered over a long term period “as needed” in patients with chronic primary insomnia for Sanofi, Inc.

2004 Principal Investigator: A double-blind, randomized, placebo controlled, parallel group, multicenter study of *MK-0928* in healthy adult volunteers participating in a 4-hour phase advanced model of transient insomnia for Merck & Co.

2005 Principal Investigator: A double-blind, randomized, placebo-controlled, multicenter, 30-night polysomnographic study of *MK-0928* in adult patients with primary insomnia for Merck & Co.

2005 Principal Investigator: A double-blind, randomized, placebo-controlled, multicenter, 30-night, polysomnographic study of *MK-0928* in elderly patients with primary insomnia for Merck & Co.

2005 Principal Investigator: A Phase III, randomized, double-blind, placebo-controlled, polysomnographic study to assess the efficacy and safety of a modified release formulation (*NBI-34060*) in primary insomnia patients with sleep maintenance problems for Neurocrine, Inc.

2005 Principal Investigator: A Phase III, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to assess the efficacy and safety of *Doxepin HCL* in primary insomnia patients with sleep maintenance difficulties for Somaxon, Inc.

2005 Principal Investigator: A randomized, double-blind, placebo-controlled, parallel-group clinical trial comparing fixed doses of 0.25 mg, 0.50 mg, and 0.75 mg of *Pramipexole (Mirapex)* administered orally to investigate the safety and efficacy in patients with idiopathic restless legs syndrome after 12-weeks for Boehringer-Ingelheim.

2005 Principal Investigator: A Randomized, double-blind, placebo-controlled, parallel group to evaluate the long term efficacy and safety of *Zolpidem MR 12.5 mg* compared to placebo when both are administered over a long term period “as needed” in patients with chronic insomnia for Sanofi.

2005 Principal Investigator: A 12-month, open label, flexible dosage (100-250 mg/day) extension study of the safety and efficacy of CEP-10953 in the treatment of patients with excessive daytime sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome, or chronic shift work sleep disorder for Cephalon.

2005 Principal Investigator: A phase II, randomized, double-blind, placebo-controlled, dose response study to assess the efficacy and safety of *Doxepin HCL* in elderly patients with primary sleep maintenance insomnia for Somaxon.

2005 Principal Investigator: A North American, 4-week, multicenter, Phase IIB Placebo controlled, randomized, multiple dose, parallel group, study of the efficacy and safety of 0.5 mg, 1.0 mg, and 2.0 mg M100907 tablets in the treatment of sleep maintenance insomnia for Adventis.

PUBLICATIONS

Faber, J.J., Williamson, G.R. and Feldman, N.T.: Lubrication of joints. J. Appl. Physiol. 22:793-799, 1967.

Parad, R., Simmons, G., Feldman, N.T. and Huber, G.: Impairment of adaptive tolerance to oxygen toxicity by systemic immunosuppression. Chest 67:42S-43S, 1975.

Feldman, N.T. and Sanders, J.: An alternate method for the fiberoptic bronchoscopic examination of the intubated patient. Amer. Rev. Resp. Dis. 111(4); 562-563, 1975.

Feldman, N.T.: Editorial: An assessment of transbronchial lung biopsy. New Eng. J. Med. 293(6):299-300, 1975.

Feldman, N.T. and Huber, G.L.: Fiberoptic bronchoscopy in the intensive care unit. Int. Anesthesiol. Clin. 14(1):31-42, 1976.

Feldman, N.T. and Ingram, R.: Treatment of chronic bronchitis and emphysema, In Current Therapy 1976. H.F. Conn. ed. Philadelphia, W.B. Saunders, 1976, p.114-119.

Pennington, J.E. and Feldman, N.T.: Pulmonary infiltrates and fever in patients with hematologic malignancy: Assessment of transbronchial biopsy. Amer. J. Med. 62(4):581-587, 1977.

McFadden, E.R., Jr. and Feldman, N.T.: Asthma: Pathophysiology and clinical correlates. Med. Clin. N. Amer. 61(6):1229-1238, 1977.

Feldman, N.T. and McFadden, E.R., Jr.: Asthma. Therapy old and new. Med. Clin. N. Amer. 61:1239-1250, 1977

Feldman, N.T., Pennington, J.E. and Ehrie, M.G.: Transbronchial lung biopsy in the compromised host. JAMA 238(13):1377-1379, 1977

Aurigemma, N.M., Feldman, N.T., Gottlieb, M., Ingram, R.H., Jr., Lazarus, J.M. and Lowrie, E.G.: Arterial oxygenation during hemodialysis. New Engl. J. Med. 297(16):871-873, 1977.

Scharf, S.M., Feldman, N.T., Goldman, M., Bruce, E., Haut, H., and Ingram, R.H., Jr.: Vocal cord closure: A cause of upper airway obstruction during controlled ventilation. Amer. Rev. Resp. Dis. 117(2):391, 1978.

Feldman, N.T. and McFadden E.R., Jr.: Occupational asthma. Comp. Ther. 4(4) 23-28, 1978.

Feldman, N.T. and Ingram, R.H., Jr.: Chronic cor pulmonale, In Yhe Heart, Fourth Edition. J.W. Hurst, ed. New York, Mcgraw-Hill. 1978. chap. 76, pp. 1485-1496.

Kreitzer, S.M., Feldman, N.T., Saunders, N.A., Ingram, R.H., Jr.: Bilateral diaphragmatic paralysis presenting as hypercapneic respiratory failure: A physiologic assessment. Am. J. Med. 65(1):87-95, 1978.

Scharf, S.M., Feldman, N.T., Grayboys, T., Wellman, J.J.: Restrictive ventilatory defect in a patient with primary pulmonary hypertension. Am. Rev. Resp. Dis. 118(2):509-513, 1978.

Haut, H.Z., Feldman, N.T., Holcomb, W.G., Ingram, R.H., Hines, E.: Electromyogram-triggered diaphragm pacer. Proceedings, New England Bioengineering Conference, 1978.

Strohl, K.P., Saunders, N.A., Feldman, N.T.: Obstructive sleep apnea in family members. New Eng. J. Med. 299: 969-973, 1978.

Scharf, S.M. , Feldman, N.T.: Case reports: Cryptococcosis. Clin. Notes Resp. Dis. 18(3):12-13, 1979.

Strohl, R.P., Feldman, N.T., Saunders, N.A., O'Connor, N.: Carbon monoxide poisoning in fire victims: A reappraisal of prognosis. J. Trauma 20(1):78-80, 1979.

Hensley, M.J., Feldman, N.T., Lazarus, M.: Diffuse pulmonary hemorrhage and rapidly progressive renal failure. an uncommon presentation of Wegener's granulomatosis. Am. J. Med. 66(5):894-898, 1979.

Strohl, K.P., Feldman, N.T.: Apical fibrobullous pulmonary disease with rheumatoid arthritis. Chest 75(6):739-741, 1979.

US Modafinil in Narcolepsy Multi-center Study Group. Randomized trial of Modafinil for the treatment of pathological somnolence in narcolepsy. Ann of Neuro. 43(1): 88-97, 1998.

US Modafinil in Narcolepsy Multi-center Study Group: Randomized trial of Modafinil as a treatment for the EDS of narcolepsy. Neurology. 2000; 54(5): 1166-75.

Feldman NT. Narcolepsy; the differential diagnosis of sleepiness and fatigue. Jacksonville Med. 52(3); 116-119, 2000.

Schwartz, JR, Feldman, NT, Fry, JM, Harsh, J.: Efficacy and safety of Modafinil for improving daytime wakefulness in patients treated previously with psychostimulants. Sleep Med. 2003 Jan; 4(1):43-9.

Feldman, NT.: Narcolepsy. South Med J. 2003 Mar; 96(3):277-82. Review.

Schwartz, JR, Feldman, NT, Bogan, RK, Nelson, MT, Hughes, RJ.: Dosing regimen effects of Modafinil for improving daytime wakefulness in patients with narcolepsy. Clinical Neuropharmacol. 2003 Sep-Oct; 26(5):252-7.

Becker, PM, Schwartz, JR, Feldman, NT, Hughes, RJ.: Effect of Modafinil on fatigue, mood, and health-related quality of life in patients with narcolepsy. Psychopharmacology (Berl). 2004 Jan; 171(2):133-9. Epub 2003 Nov. 25.

Schwartz, JR, Feldman, NT, Bogan, RK.: Dose effects of Modafinil in substaining wakefulness in narcolepsy patients with residual evening sleepiness. J Neuropsychiatry Clin Neurosci. 2005 Summer; 17(3):405-12. Erratum in: J Neuropsychiatry Clin Neurosci. 2005 Fall; 17(4):561.

LETTERS TO THE EDITOR

Martin, M.M., Feldman, N.T.: Promoting sleep fro the MI patient. Crit. Care Nurse 10(1):74, 1990. (Comment on critical care nursing 9(3):44-49, 1989.)

Feldman, N.T., Singh, H.: Nocturnal home oximetry in detecting the sleep apnea/hypopnea syndrome and in working up hypersomnolence (letter, comment). Ann. Inter, Med. 120(5):439-440, 1994. (comment on: Ann. Intern. Med. 119(6):449-453, 1993.)

Gill, J., Feldman, N.T.: Sleep disorders and chronic fatigue (letter, comment). South. Med. J. 87(12):1289-1290, 1994. (comment on South. Med. J. 87(4):465-470,1994.)

Feldman, NT : Xyrem safety: the debate continues. Sleep Med. 2009 April: 10(4):405-6 Epub 2009 March 21

ABSTRACTS

Goodenough, S., Simmons, G., Mullane, J., Feldman, N.T. and Huber, G.: Impairment of pulmonary anitbacterial defenses by experimental stress, Clin. Res. 22:442, 1974.

Parad, R., Simmons, G., Feldman, N.T. and Huber, G.: Impairment of adaptive tolerance to oxygen toxicity by systemic immunosuppression. Clin. Res. 22:425, 1974.

Scharf, S.M., Feldman, N.T., Goldman, M.D., and Ingram, R.H., Jr.: Mechanism producing inspiration upper airway obstruction during electrophrenic respiration and ventilation with iron lung. Amer. Rev. Resp. Dis. 115:160, 1977.

Kreitzer, S.M., Feldman, N.T., Saunders, N.A., Ingram, R.H., Jr.: Bilateral diaphragmatic paralysis with hypercapneic respiratory failure. A physiologic assessment. Am. Rev. Resp. Dis., 1978.

Haut, H.Z., Feldman, N.T., Holcomb, W.G., ingram, R.H., Jr.: Electromyographic triggered diaphragmatic pacing. Proceedings New England Bioengineering Conference, 1978.

Feldman NT, Berrios J. Simultaneous uvulopalatopharyngoplasty (UPPP) and base-of-tongue (BOT) radiofrequency ablation (Somnoplasty) for the treatment of obstructive sleep apnea (OSA). Sleep. 23(abstract suppl) A83, 2000.

Schwartz JR, Feldman NT, Fry JM. Effect of Provigil (modafinil) on excessive daytime sleepiness associated with narcolepsy in patients who previously received unsatisfactory treatment with dextroamphetamine, methylphenidate, or pemoline. Sleep. 23 (abstract suppl) A306, 2000.

Feldman NT, Schwartz JR, Harsh J. Effect of Provigil (modafinil) on the quality of life and mood of patients who previously received unsatisfactory treatment with dextroamphetamine, methylphenidate, or pemoline for excessive daytime sleepiness associated with narcolepsy. Sleep. 23 (abstract suppl) A307, 2000.

Feldman NT, Walsleben J and the US Modafinil in sleep apnea multicenter study group. Effect of modafinil on nighttime sleep and quality of life in patients with sleep apnea and residual daytime sleepiness despite effective NCPAP therapy. Chest. 118;4(suppl), 2000.

Schwartz JR, Feldman NT, Becker P, Nelson M, Bogan R. Dose response effects of modafinil in narcolepsy. Sleep. 24(abstract suppl), 2001.

Feldman NT. Sodium oxybate therapy significantly improves the excessive daytime sleepiness associated with narcolepsy. Sleep. 24(abstract suppl), 2001.

Feldman, NT. Sodium oxybate, alone and in combination with modafinil, is safe and well-tolerated for the treatment of narcolepsy. Sleep 2005; 28 (Suppl):214.

George CF, Feldman N, Zheng Y, Steininger TL, Grzeschik SM, Lai C, Zheng Y
A 2-week polysomnographicm safety study of sodium Oxybate in obstructive sleep apnea syndrome. Sleep Breath, 2010 Jan 18

George CF, Feldman N, Inhaber N, Steininger TL, Grzeschik SM, Lai C, Zheng Y.
A safety trial of sodium Oxybate in patients with obstructive sleep apnea: Acute effects on sleep-disordered breathing. Sleep Med 2010 Jan:11(1):38-42

Feldman NT Clinical Perspective: monitoring sodium oxybate-treated narcolepsy treated patients for the development of sleep-disordered breathing. Sleep Breath 2010 Feb; 14(1):77-9